To the Editor: We read with great interest the article by Murray B. Stein, M.D., and his colleagues (1), which reported on a double-blind randomized study. Randomized controlled trials are always cited as the gold standard for detecting treatment efficacy. However, they often can be flawed in design and are not immune to bias. The relevance of such a study has been criticized on the grounds of small group size, selection bias, and improper random assignment to groups.